This study is looking at a new way to treat chronic rhinosinusitis (CRS), a long-lasting inflammation of the sinuses, in adults. It's testing a procedure called Airiver ESSpand DCB, which uses a balloon coated with paclitaxel (a medication) to open up the sinuses after traditional endoscopic sinus surgery (ESS). The study wants to see if this combination treatment is safe after 30 days and how well it works after 6 months. You might be able to join if you are 18 or older, have a confirmed diagnosis of CRS with or without nasal polyps, and need endoscopic sinus surgery. The study is currently recruiting 300 participants.

Study design

This is a randomized, controlled, double-blind study involving 300 participants. Participants will either receive traditional ESS or ESS followed by the Airiver ESSpand DCB procedure.

What's involved

All participants will undergo traditional endoscopic sinus surgery (ESS). Some will also have the Airiver ESSpand DCB procedure. Safety will be checked at 30 days, and effectiveness at 6 months.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for safety for 30 days and for efficacy for 6 months after their procedure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.